ENSC - Ensysce Biosciences, Inc. Stock Price, Fair Value and News

0.63USD0.00 (0.00%)Market Closed

Market Summary

USD0.630.00

Market Closed

0.00%

ENSC Stock Price

View Fullscreen

ENSC RSI Chart

ENSC Valuation

Market Cap

4.8M

Price/Earnings (Trailing)

-0.41

Price/Sales (Trailing)

2.74

EV/EBITDA

1.69

Price/Free Cashflow

-0.45

ENSC Price/Sales (Trailing)

ENSC Profitability

EBT Margin

113.72%

Return on Equity

-337.69%

Return on Assets

-227.64%

Free Cashflow Yield

-221.43%

ENSC Fundamentals

ENSC Revenue

Revenue (TTM)

1.7M

Rev. Growth (Yr)

-61.28%

Rev. Growth (Qtr)

-40.64%

ENSC Earnings

Earnings (TTM)

-11.6M

Earnings Growth (Yr)

-42.19%

Earnings Growth (Qtr)

11.07%

Breaking Down ENSC Revenue

Last 7 days

21.2%

Last 90 days

-32.3%

Trailing 12 Months

-77.0%

How does ENSC drawdown profile look like?

ENSC Financial Health

Current Ratio

2.87

Debt/Equity

1.46

Debt/Cashflow

-2.12

ENSC Investor Care

Shares Dilution (1Y)

490.48%

Diluted EPS (TTM)

-3.47

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	1.7M	0	0	0
2023	2.7M	3.0M	3.1M	2.2M
2022	3.9M	3.6M	2.7M	2.5M
2021	3.8M	3.7M	3.6M	3.5M
2020	0	0	0	3.9M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Ensysce Biosciences, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 02, 2023	gower bob g	bought	44,087	0.4883	90,287	-
Mar 01, 2023	gower bob g	bought	128,979	0.4777	270,000	-
Feb 28, 2023	gower bob g	bought	53,371	0.4883	109,300	-
Dec 09, 2022	gower bob g	bought	500,000	1.4	357,143	-
May 26, 2022	kirkpatrick lynn	bought	14,215	0.5265	27,000	chief executive officer
May 25, 2022	kirkpatrick lynn	bought	34,083	0.4869	70,000	chief executive officer
Jun 30, 2021	gower bob g	acquired	-	-	7,919,030	-
Jun 30, 2021	kirkpatrick lynn	acquired	-	-	284,851	chief executive officer
Jun 30, 2021	chang william h	acquired	-	-	2,242,190	-
Jun 30, 2021	chang william h	acquired	-	-	353,451	-

Which funds bought or sold ENSC recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 15, 2024	Tower Research Capital LLC (TRC)	added	29.48	-234	6,451	-%
May 15, 2024	SABBY MANAGEMENT, LLC	new	-	182,184,000	182,184,000	0.10%
May 15, 2024	Main Street Group, LTD	new	-	289	289	-%
May 13, 2024	RENAISSANCE TECHNOLOGIES LLC	reduced	-3.68	-4,000	8,000	-%
May 13, 2024	GEODE CAPITAL MANAGEMENT, LLC	added	12.51	-2,539	14,474	-%
May 13, 2024	UBS Group AG	added	420,233	9,959	9,962	-%
May 10, 2024	VANGUARD GROUP INC	unchanged	-	-4,904	14,362	-%
May 10, 2024	BlackRock Inc.	unchanged	-	-264	770	-%
May 10, 2024	WELLS FARGO & COMPANY/MN	added	4.17	-5.00	20.00	-%
May 09, 2024	Plante Moran Financial Advisors, LLC	unchanged	-	-5.00	16.00	-%

Are Funds Buying or Selling ENSC?

Are funds buying ENSC calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own ENSC

No. of Funds

Unveiling Ensysce Biosciences, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	lincoln park capital fund, llc	792%	124,008	SC 13G/A
Jul 18, 2023	gower bob g	5.7%	161,586	SC 13D/A
Feb 14, 2023	hg vora capital management, llc	2.1%	237,750	SC 13G/A
Feb 14, 2023	cvi investments, inc.	4.9%	336,872	SC 13G/A
Feb 07, 2023	lincoln park capital fund, llc	9.99%	1,501,055	SC 13G
Dec 16, 2022	cvi investments, inc.	7.8%	5e+05	SC 13G
Feb 14, 2022	hg vora capital management, llc	24.6%	7,130,000	SC 13G/A
Feb 14, 2022	glazer capital, llc	0.0%	0	SC 13G/A

Recent SEC filings of Ensysce Biosciences, Inc.

View All Filings

Date Filed	Form Type	Document
May 13, 2024	8-K	Current Report
May 13, 2024	10-Q	Quarterly Report
May 09, 2024	8-K	Current Report
May 01, 2024	EFFECT	EFFECT
Apr 19, 2024	POS AM	POS AM
Apr 05, 2024	EFFECT	EFFECT
Apr 03, 2024	CORRESP	CORRESP
Mar 29, 2024	8-K	Current Report
Mar 26, 2024	S-1/A	Initial Public Offering
Mar 15, 2024	8-K	Current Report

Peers (Alternatives to Ensysce Biosciences, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	28.49%	6.05%	-8.53	7.44	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.9B	2.0B	2.79%	-21.33%	-56.9	9.43	75.20%	68.82%
BMRN	14.7B	2.5B	-14.30%	-15.94%	71.65	5.96	13.74%	186.89%
INCY	12.8B	3.8B	8.33%	-10.25%	17.2	3.4	8.58%	129.81%
MID-CAP
BBIO	5.6B	107.9M	20.58%	115.45%	-10.31	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-13.99%	-52.79%	-12.02	9.57	394.93%	39.61%
AXSM	3.6B	251.0M	9.96%	-0.29%	-12.28	14.5	73.58%	-86.73%
ARWR	3.1B	240.7M	9.94%	-31.73%	-6.53	12.77	-1.03%	-213.43%
ACAD	2.4B	813.8M	-14.08%	-36.34%	-1.4K	3	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	3.06%	35.16%	29.91	4.73	60.38%	-34.49%
NVAX	1.8B	996.6M	234.45%	75.34%	-4.58	1.83	-26.66%	65.49%
CRBP	480.9M	881.7K	21.10%	351.81%	-14.25	481.06	-77.61%	33.36%
INO	310.9M	4.9M	8.40%	53.85%	-2.49	63.89	-54.97%	48.23%
IBIO	17.1M	2.1M	4.76%	108.64%	-0.74	7.61	-13.45%	69.54%

Ensysce Biosciences, Inc. News

Latest updates

Ensysce Biosciences, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In null)

Income Statement (Quarterly)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2
Revenue	-40.6%	306	515	435	490	790	1,433	279	207	603	1,635	1,201	445	251	539	828	1,825
Operating Expenses	-41.5%	2,149	3,671	3,143	2,784	3,351	7,634	6,443	7,263	5,406	3,662	18,088	857	775	1,611	1,232	1,686
S&GA Expenses	-100.0%	-	1,438	1,228	1,141	1,555	1,099	1,687	1,951	2,266	1,454	16,373	394	490	256	339	281
R&D Expenses	-65.1%	779	2,233	1,915	1,644	1,796	6,535	4,756	5,311	3,140	2,208	1,715	463	284	1,253	893	1,404
EBITDA Margin	95.7%	2.05*	1.05*	0.65*	0.68*	0.77*	0.83*	0.75*	0.57*	0.76*	0.93*	1.01*	1.03*	0.82*	-	-	-
Interest Expenses	262.0%	1,248	345	8.00	-	1.00	52.00	5.00	38.00	15.00	12.00	25.00	910	348	397	216	202
Income Taxes	-	-	-	-	-	-	-	-	-	-	-	-	-	2.00	-131	-504	694
Earnings Before Taxes	-	-	-	-	-	-	-	-	-	-	-	-	-	-1,772	741	-285	3,304
EBT Margin	27.7%	1.14*	0.89*	0.63*	0.66*	0.73*	0.79*	0.73*	0.54*	0.51*	0.56*	0.55*	0.53*	0.52*	-	-	-
Net Income	11.1%	-3,116	-3,504	-2,690	-2,239	-2,191	-5,478	-9,855	-7,923	-950	-10,057	-17,199	-957	-911	-2,207	1,571	887
Net Income Margin	-38.8%	-6.61*	-4.76*	-4.00*	-6.60*	-9.39*	-9.59*	-10.56*	-9.91*	-7.51*	-8.25*	-5.86*	-0.67*	-0.17*	-	-	-
Free Cashflow	-89.2%	-3,408	-1,801	-2,262	-3,108	-3,606	-3,295	-6,714	-4,440	-3,437	-3,767	-3,824	-132	-517	-	-	-

Balance Sheet

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Balance Sheet																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	87.4%	5,074	2,708	3,219	6,358	3,915	5,885	8,290	7,949	12,371	16,417	9,718	9,196	12,980	13,135	13,289	13,412	61,602	196,512	207,211	206,357	205,555
Current Assets	105.2%	4,697	2,289	2,758	5,855	3,371	5,299	7,662	7,195	11,658	15,663	8,921	8,358	228	348	102	186	274	1,200	1,378	1,469	1,611
Cash Equivalents	203.0%	3,404	1,124	1,464	3,829	1,416	3,148	4,503	3,735	8,441	12,265	6,846	8,012	18.00	194	53.00	124	168	1,061	1,274	1,402	1,507
Net PPE	-	-	-	-	-	-	-	-	-	-	-	-	50*	100*	151*	-	-	-	351*	-	-	-
Liabilities	-50.8%	1,654	3,359	2,061	2,565	4,067	9,915	14,712	8,747	11,260	24,575	10,103	4,029	11,087	7,010	11,774	16,107	57,084	17,504	13,662	13,162	12,779
Current Liabilities	-50.9%	1,636	3,333	2,031	2,517	3,976	9,464	11,910	8,248	8,802	16,482	7,031	4,029	319	7,010	452	794	3,494	2,771	1,125	327	387
Long Term Debt	-	-	-	-	-	-	-	5,000	5,000	-	593	5,000	-	-	670	-	-	-	-	-	-	-
Shareholder's Equity	625.2%	3,421	-651	1,485	3,793	167	-4,029	-	-	1,111	-	-	5,167	1,894	5,000	1,515	5,000	4,518	49,512	5,000	5,000	5,000
Retained Earnings	-2.6%	-124,673	-121,557	-118,052	-115,400	-113,100	-110,931	-105,409	-95,511	-87,500	-85,845	-75,005	-57,841	-2,919	-55,958	1,514	-2,695	1,656	-136	2,820	2,467	2,048
Additional Paid-In Capital	5.9%	128,422	121,234	119,538	119,482	113,294	107,217	99,314	95,016	88,900	77,967	74,897	63,251	4,813	49,518	63.00	-	2,861	5,136	2,179	2,533	2,952
Shares Outstanding	133.0%	7,329	3,146	2,864	2,670	1,285	534	139	128	114	103	101	26.00	66.00	-	-	-	-	-	-	-	-
Minority Interest	0.0%	-328	-328	-327	-326	-319	-315	-327	-305	-279	-279	-279	-243	-221	-217	-	-	-	-	-	-	-
Float	-	-	-	-	4,600	-	-	-	18,800	-	-	-	-	-	-	-	3,700	-	-	-	193,800	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-89.2%	-3,408	-1,801	-2,262	-3,108	-3,606	-3,295	-6,714	-4,440	-3,437	-3,767	-3,824	-132	-517	-533	-152	-326	-234	-425	-272	-432	-294
Share Based Compensation	-94.7%	33.00	629	56.00	77.00	117	217	157	296	402	17.00	25.00	36.00	44.00	59.00	52.00	36.00	32.00	-	-	-	-
Cashflow From Investing	-	-	-	-	-	-	-	-	-	5.00	-	-	-	-62.50	183,407	-182,807	48,179	134,625	11,230	144	328	151
Cashflow From Financing	289.4%	5,689	1,461	-102	5,522	1,875	1,940	7,483	-265	-391	9,187	2,659	7,854	613	-	300	136,084	-135,283	-11,017	-	-	-8.64
Buy Backs	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	136,283	-	-	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

ENSC Income Statement

2024-03-31

Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Income Statement [Abstract]
Federal grants	$ 305,722	$ 789,635
Operating expenses:
Research and development	778,904	1,796,015
General and administrative	1,369,782	1,554,855
Total operating expenses	2,148,686	3,350,870
Loss from operations	(1,842,964)	(2,561,235)
Other income (expense):
Change in fair value of convertible notes		146,479
Change in fair value of liability classified warrants	8,955	219,028
Interest expense, net	(1,248,065)	(1,497)
Other income and expense, net	(34,489)	5,419
Total other income, net	(1,273,599)	369,429
Net loss	(3,116,563)	(2,191,806)
Net loss attributable to noncontrolling interests	(74)	(3,941)
Deemed dividend related to warrants down round provision	290	8,309
Net loss attributable to common stockholders	$ (3,116,779)	$ (2,196,174)
Net loss per basic and diluted share:
Net loss per share attributable to common stockholders, basic	$ (0.55)	$ (2.08)
Net loss per share attributable to common stockholders, diluted	$ (0.55)	$ (2.08)
Weighted average common shares outstanding, basic	5,694,466	1,054,202
Weighted average common shares outstanding, diluted	5,694,466	1,054,202

ENSC Balance Sheet

2024-03-31

Consolidated Balance Sheets (Unaudited) - USD ($)	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 3,404,349	$ 1,123,604
Unbilled receivable	96,224	97,561
Prepaid expenses and other current assets	1,196,067	1,067,703
Total current assets	4,696,640	2,288,868
Other assets	377,550	419,217
Total assets	5,074,190	2,708,085
Current liabilities:
Accounts payable	981,720	1,936,007
Accrued expenses and other liabilities	408,435	542,260
Notes payable and accrued interest	245,973	854,697
Total current liabilities	1,636,128	3,332,964
Long-term liabilities:
Liability classified warrants	17,433	26,388
Total long-term liabilities	17,433	26,388
Total liabilities	1,653,561	3,359,352
Commitments and contingencies (Note 6)
Stockholders’ equity (deficit)
Preferred stock, $0.0001 par value, 1,500,000 shares authorized, no shares issued and outstanding at March 31, 2024 (unaudited) and December 31, 2023
Common stock, $0.0001 par value, 250,000,000 shares authorized at March 31, 2024 (unaudited) and December 31, 2023; 7,329,253 and 3,146,157 shares issued at March 31, 2024 (unaudited) and December 31, 2023, respectively; 7,329,172 and 3,146,076 shares outstanding at March 31, 2024 (unaudited) and December 31, 2023, respectively	733	315
Additional paid-in capital	128,422,232	121,233,901
Accumulated deficit	(124,673,853)	(121,557,074)
Total Ensysce Biosciences, Inc. stockholders’ equity (deficit)	3,749,112	(322,858)
Noncontrolling interests in stockholders’ deficit	(328,483)	(328,409)
Total stockholders’ equity (deficit)	3,420,629	(651,267)
Total liabilities and stockholders’ equity (deficit)	$ 5,074,190	$ 2,708,085

About Ensysce Biosciences, Inc.

Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, engages in developing various prescription drugs for severe pain relief in opioid misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection platform, an abuse-resistant opioid prodrug technology; and Multi-Pill Abuse Resistance platform, an over-dose protection opioid prodrug technology. The company is developing PF614, a TAAP prodrug candidate of oxycodone for the treatment of acute or chronic pain; and PF614-MPAR, a combination product of PF614 and nafamostat for overdose protection against excessive oral ingestion, as well as an oral and inhalation drug product of nafamostat for use against coronaviral infections and other pulmonary diseases, such as cystic fibrosis. It is also developing PF614, an extended-release oxycodone-derivative which releases clinically effective oxycodone; PF8001 and PF8026 are extended and immediate-release prodrugs of amphetamine for ADHD medication abuse. The company is based in La Jolla, California.

CEO	Dr. D. Lynn Kirkpatrick Ph.D.
WEBSITE	ensysce.com
INDUSTRY	Biotechnology
EMPLOYEES	7

Ensysce Biosciences, Inc. Frequently Asked Questions

What is the ticker symbol for Ensysce Biosciences, Inc.? What does ENSC stand for in stocks?

ENSC is the stock ticker symbol of Ensysce Biosciences, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Ensysce Biosciences, Inc. (ENSC)?

As of Fri May 17 2024, market cap of Ensysce Biosciences, Inc. is 4.78 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ENSC stock?

You can check ENSC's fair value in chart for subscribers.

What is the fair value of ENSC stock?

You can check ENSC's fair value in chart for subscribers. The fair value of Ensysce Biosciences, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Ensysce Biosciences, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ENSC so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Ensysce Biosciences, Inc. a good stock to buy?

The fair value guage provides a quick view whether ENSC is over valued or under valued. Whether Ensysce Biosciences, Inc. is cheap or expensive depends on the assumptions which impact Ensysce Biosciences, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ENSC.

What is Ensysce Biosciences, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, ENSC's PE ratio (Price to Earnings) is -0.41 and Price to Sales (PS) ratio is 2.74. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ENSC PE ratio will change depending on the future growth rate expectations of investors.